These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 6895408)

  • 1. [Clearance concept applied to pharmacokinetics: 2. Experience with tolamolol (beta-blocking agent) in renal insufficiency (author's transl)].
    Balant L; Gorgia A; Marmy A; Tschopp JM
    Nephrologie; 1980; 1(4):177-82. PubMed ID: 6895408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consequences of renal insufficiency on the hepatic clearance of some drugs.
    Balant LP; Dayer P; Fabre J
    Int J Clin Pharmacol Res; 1983; 3(6):459-74. PubMed ID: 6147317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Butofilolol pharmacokinetics in chronic renal insufficiency.
    Jeanniot JP; Houin G; Ledudal P; Cautreels W; Giudicelli CP; Tillement JP
    Int J Clin Pharmacol Res; 1984; 4(3):165-73. PubMed ID: 6149194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clearance concept applied to pharmacokinetics: 1. Application for the study of tolamolol (beta-blocking agent) in healthy volunteers (author's transl)].
    Balant L; Faulkner JK; Tozer TN
    Nephrologie; 1980; 1(4):172-6. PubMed ID: 6895407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of nitrendipine in patients with renal failure: comparison to normal subjects.
    Aronoff GR
    J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S974-6. PubMed ID: 6085387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of renal failure on the hepatic clearance of bufuralol in man.
    Balant L; Francis RJ; Tozer TN; Marmy A; Tschopp JM; Fabre J
    J Pharmacokinet Biopharm; 1980 Oct; 8(5):421-38. PubMed ID: 6114166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of metabolites in the relationship between pharmacokinetics and the effect of beta blockers. Studies on tolamolol and bufuralol].
    Tschopp JM; Gorgia A; Balant L; Revillard C; Francis RJ; Fabre FJ
    Schweiz Med Wochenschr; 1978 May; 108(20):756-64. PubMed ID: 26114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacokinetics of digitoxin in chronic renal failure (author's transl)].
    Peters U; Grabensee B; Hausamen TU; Fritsch WP; Grosse-Brockhoff F
    Dtsch Med Wochenschr; 1977 Jan; 102(4):109-15. PubMed ID: 832589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacokinetics of cefotaxime in patients with chronic renal impairment (author's transl)].
    Fillastre JP; Ings RM; Leroy A; Humbert G; Godin M
    Nouv Presse Med; 1981 Feb; 10(8):574-9. PubMed ID: 6259595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacokinetics of triamterene and its active metabolites in renal insufficiency (author's transl)].
    Grebian B; Geissler HE; Knauf H; Mutschler E; Schnippenkoetter I; Völger KD; Wais U
    Arzneimittelforschung; 1978; 28(8):1420-5. PubMed ID: 582410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of mexiletine in renal insufficiency.
    Baudinet G; Henrard L; Quinaux N; El Allaf D; de Landsheere C; Carlier J; Dresse A
    Acta Cardiol Suppl; 1980; (25):55-65. PubMed ID: 6966453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics of bucindolol and its major metabolite in essential hypertension.
    Meredith PA; Kelman AW; McSharry DR; Vincent J; Reid JL
    Xenobiotica; 1985 Nov; 15(11):979-85. PubMed ID: 4082637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and metabolism of zopiclone.
    Gaillot J; Heusse D; Hougton GW; Marc Aurele J; Dreyfus JF
    Int Pharmacopsychiatry; 1982; 17 Suppl 2():76-91. PubMed ID: 7188377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the pharmacokinetics of talinolol, a new beta 1-receptor blocking agent.
    Haustein KO; Fritzsche K
    Int J Clin Pharmacol Ther Toxicol; 1981 Sep; 19(9):392-5. PubMed ID: 6117520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.
    Kirch W; Köhler H; Berggren G; Braun W
    Clin Nephrol; 1982 Aug; 18(2):88-94. PubMed ID: 7140021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetics of midazolam after i.v. administration (author's transl)].
    Amrein R; Cano JP; Eckert M; Coassolo P
    Arzneimittelforschung; 1981; 31(12a):2202-5. PubMed ID: 7199322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetic study of guanfacine in patients with renal insufficiency and in patients under chronic dialysis (author's transl)].
    Kiechel JR; Lavene D; Gurret M; Coustenoble J; Petrover M; Godin M; Fillastre JP
    Nephrologie; 1980; 1(2):73-81. PubMed ID: 7029332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetics of two beta blocking drugs: detection of a pharmacogenetic abnormality].
    Balant L; Gorgia A; Tschopp JM; Revillard C; Fabre J
    Schweiz Med Wochenschr; 1976 Oct; 106(41):1403-7. PubMed ID: 12563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.